SOUTH SAN FRANCISCO, Calif., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a
clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the company will
host a live conference call and webcast on Monday, December 12, 2016 at 8:30 a.m. EST (5:30 a.m. PST) to discuss recent CB-839
clinical data presentations at the San Antonio Breast Cancer Symposium, the EORTC-NCI-AACR Symposium, and other recent corporate
highlights and business developments.
The live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The conference
call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference ID 36690670.
Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain
available for replay on Calithera’s website for 30 days.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small
molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead
product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes
advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being
evaluated in Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class
immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell
suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation,
growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is currently in a Phase I
clinical trial. Calithera is headquartered in South San Francisco, California. For more information about Calithera,
please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events,
conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to
the safety, tolerability and efficacy of CB-839, and the company’s plans to continue development of CB-839. Because such
statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such
forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical
development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not
confirm any safety, potency or other product characteristics described or assumed in this press release. Such product
candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to
any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these
and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak
only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking
statements to reflect future events or circumstances.
CONTACT: Jennifer McNealey ir@Calithera.com 650-870-1071
